Detalhe da pesquisa
1.
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Oncotarget
; 6(31): 32228-43, 2015 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26334096